Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)

Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with resectable Gastric cancer (GC) or Gastroesphageal Junction cancer (GEJC) The addition of Avelumab to the perioperative chemotherapy in GC and GEJC patients may increase pathological responses by a synergic effect activating the immune response. Conclusively, the survival of these patients would improve. The primary objective is to investigate whether the addition of avelumab to FLOT chemotherapy (docetaxel, oxaliplatin and fluorouracil/leucovorin) improves efficacy in terms of pathological complete response (pCR) rate, in GC and GEJC patients compared to the historical data of chemotherapy alone in the neoadjuvant setting.

NCT Number	NCT03979131
Lead Sponsor	Vall d'Hebron Institute of Oncology
Conditions	Gastroesophageal Junction Adenocarcinoma, Stomach Neoplasms
Enrollment	40 participants
Start Date	2019-08-22
Primary Completion	2023-03-15 (estimated)
Study Completion	2026-06-15 (estimated)
Updated on ClinicalTrials.gov	2024-11-07